Plymouth expert honoured to work on Sir David Attenborough film
A university researcher has said it was a "huge honour" after he helped create the latest Sir David Attenborough documentary. Dr Bryce Stewart, an associate professor at the university, worked with broadcasters on the film Ocean.Dr Stewart's guidance was required when the crew showcased a carefully controlled study as part of the film to better understand the effects of dredging - a method of fishing which sees boats tow a heavy metal frame with a bag or net - on marine life.He said: "It was a huge honour to work on the film Ocean with David Attenborough, and I had the privilege of helping film some of the scenes and advising on the script."
He said: "The film is stunningly beautiful while being highly confronting at times. "However, it ends with a message of hope – that is, if you properly protect marine ecosystems and manage human activities sustainably, then the ocean can bounce back at an astonishing rate. "Achieving that balance and recovery is the focus of my research at Plymouth."
As part of his involvement, Dr Stewart and colleagues at the Marine Biological Association worked closely with the production team to highlight environmental challenges and the importance of conservation work.Ocean was originally released in cinemas worldwide, and will be available for streaming globally on National Geographic on 7 June and Disney+ from 8 June, in celebration of World Ocean Day.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
5 minutes ago
- The Independent
Dilly Dally the sea turtle returns to the ocean after flipper amputation
An adolescent loggerhead sea turtle named Dilly Dally crawled into the Atlantic Ocean Wednesday morning, months after having a front flipper amputated at a Florida turtle hospital. The turtle was brought to Loggerhead Marinelife Center in January suffering from predator wounds to the front flipper. The veterinary crew at the Juno Beach facility assisted in Dilly Dally's rehabilitation and care. 'Every time we can release a turtle back into the wild is special and not just for us but for all the interns and volunteers and everyone that puts an effort to getting these turtles back out there. It's always a really special day,' said Marika Weber, a veterinary technician at the center. Stormy weather on Wednesday almost caused Dilly Dally's release to be postponed. But they packed the turtle up and drove the short distance to the beach. A crowd of beachgoers cheered as the turtle made its way to the ocean. A satellite tracking device attached to Dilly Dally's shell will allow the center and the public to follow her journey. The center partnered with the Smithsonian to get the satellite tag, which was attached on Tuesday. 'So now Dilly Dally has an active live satellite tag on her and we can get real-time data on where she goes, which is really exciting because we don't really know what happens to our three flipper turtles once you release them, Weber said. 'Now we know if their migration or foraging patterns change and it'll be really helpful to see what happens to these patients.' All sea turtles are endangered or threatened species. 'So every sea turtle that we can save and get back out there is the win for the species.' Follow Dilly Dally's journey at Marinelife Turtle Tracker.
Medical News Today
3 hours ago
- Medical News Today
Colon cancer: Exercise as important as drugs in preventing recurrence
Could exercise be 'better than a drug' at preventing colon cancer recurrence? Image credit: Connect Images/. Colorectal cancer is the third most common cancer worldwide, and the second leading cause of cancer deaths. Treatments include surgery, radiotherapy and chemotherapy. After initial treatment, people are advised to follow a healthy lifestyle, often in conjunction with further drug treatments to try and reduce the chance of recurrence. Now, a study has found that a structured exercise program could be more effective than drug treatments in preventing colon cancer recurrence. Patients following a supervised exercise program had a 28% lower risk of recurrence, and a 37% lower risk of death from any cause than those who were not. Now, a study led by Canadian scientists has found that a structured exercise program following surgery and chemotherapy for colon cancer reduced patients' chance of cancer recurring by 28% compared with patients given only health advice. Experts have said these results suggest exercise could be 'better than a drug' at preventing colon cancer recurrence. Speaking to the Science Media Centre, David Sebag-Montefiore, MB BS, MRCP, FRCP, the Audrey and Stanley Burton Professor of Clinical Oncology and Health Research, University of Leeds, United Kingdom, who was not involved in the trial, commented that: 'This is excellent news for future patients with bowel cancer and is likely to bring additional health benefits […[ The great appeal of a structured moderate intensity exercise is that is offers the benefits without the downside of the well-known side effects of our other treatments.' All those enrolled in the trial, between 2009 and 2024, had undergone surgery for stage 3 or high-risk stage 2 colon cancer, followed by adjuvant chemotherapy to help prevent the cancer returning. They ranged in age from 19 to 84 years, with a median age of 61. Most participants had a body mass index (BMI) indicating overweight or obesity, and none exercised for more than 150 minutes per week before the trial. Researchers randomly assigned all participants to one of two groups. The exercise group — made up of 445 patients — worked with a certified physical activity consultant for 3 years. For the first 6 months the consultants saw them every week, then fortnightly for the second 6 months, and monthly for next 2 years. These participants could choose the type, frequency and intensity of aerobic exercise, but the aim was to achieve the equivalent of 3-4 brisk 45-60 minute walks a week. The health-education group (444 patients) received general health-education materials promoting physical activity and healthy nutrition in addition to standard surveillance. At a median follow-up of 7.9 years, 93 people in the exercise group and 131 in the health-education group had experienced a recurrence of their cancer, a new primary cancer, or had died. In total, 107 died from any cause — 41 in the exercise group, 66 in the health-education group. People in the exercise group did not lose weight, but saw a general improvement in physical functioning and significantly longer disease-free survival, with an annual incidence of recurrence, new primary cancer, or death of 3.7%, compared with 5.4% in the health-education group. In the exercise group, 80.3% of patients were disease-free after 5 years, compared with 73.9% of the health-education group. Lead author on the study, Kerry S. Courneya, PhD, Professor and Canada Research Chair in Physical Activity and Cancer at the University of Alberta in Edmonton, Canada, told Medical News Today that the most important finding of their study was the overall improvement in survival. Julie Gralow, MD, Chief Medical Officer of the American Society of Clinical Oncology (ASCO), who was not involved in the trial, said the findings suggest that exercise could be 'better than a drug' for cancer patient outcomes, because it does not have the related side effects. However, she cautioned: 'I did not mean to suggest that we omit drugs in favor of exercise, my intention was to compare the magnitude of benefit we get from standard therapies to what exercise achieved in terms of reduction of recurrences and deaths, also taking toxicity into account.' She added that while there were effective drugs that help prevent recurrence in patients with particular mutations for colon cancer, 'exercise's benefit in colon cancer patients is not restricted to these specific mutations.' Courneya emphasized the benefits of their program: 'The 'side effects' of exercise are almost all good (fitter, stronger, less fatigue, less depression, lower [cardiovascular disease] risk, etc.). I think exercise keeps having an effect on new primary cancers and possibly other causes of death. Intervention participants were still doing more exercise than health education at years 4 and 5.' A supervised exercise program can also be much cheaper than medication. 'The [physical activity] intervention was maybe 3,000 to 5,000 [Canadian dollars] whereas it is not uncommon for some cancer drugs to be 10s of thousands and even reach 100,000,' Courneya added. Vicky Coyle, U.K. lead researcher for the trial and Clinical Professor at Queen's University Belfast, Northern Ireland, told MNT that: 'Our study gives clear, encouraging evidence that physical activity can reduce the risk of cancer returning for some people with colon cancer. We now need to work with policymakers and healthcare providers to embed exercise into treatment plans where appropriate.' Joe Henson, PhD, Associate Professor in Lifestyle Medicine at the University of Leicester, who led exercise sessions in Leicester, U.K. for the trial, highlighted the need for support. 'Despite its proven benefits, many people still face barriers to engaging in regular exercise. This study shows how important it is to make exercise advice a routine part of cancer care and to offer people tailored support,' Henson told us. Although she emphasizes the importance of exercise to her own patients, Gralow noted that implementing exercise programs like those in this study could be difficult: 'I question whether most clinics have enough personnel to accommodate this number of visits (especially since prior observational data suggests many other cancer types — including common ones like breast and prostate cancer — benefit from exercise). I also question whether all or even most patients are willing to come in this often.' 'So,' she said, 'we need to find alternative ways to support our patients in incorporating exercise into their lives that do not require clinic visits but do provide regular support and encouragement. And we need to make sure we, the clinicians, are recommending this (a prescription for exercise!).' Colorectal Cancer Cancer / Oncology Sports Medicine / Fitness
Daily Mail
3 hours ago
- Daily Mail
Prescription pill taken by 9million is linked to devastating motor neurone disease, researchers find
Antidepressants, taken by some 8.6 million people in the UK, could raise the risk of motor neurone disease, a major study has suggested. Scandinavian researchers also found that other commonly prescribed drugs, like anxiolytics used to treat anxiety disorders, sleeping pills and sedatives were also linked to an increased risk of the disabling condition. Motor neurone disease, of which amyotrophic lateral sclerosis (ALS) is the most common form, is an incurable, muscle-wasting condition that eventually stops a patient from being able to move, talk and even eat. Now, research has suggested that being prescribed any of these medications just twice over the course of a lifetime could raise the chance of developing the condition by up to 34 per cent. Scientists found the risk remained even if the drugs were taken more than five years before diagnosis. However other scientists have urged caution over the results of the study, suggesting the link lies with the fact mental health patients are more likely to develop MND, rather than medication. Professor Ammar Al-Chalabi, a specialist in complex disease genetics at King's College London warned: 'Association is not causation. That is especially important here. 'We already know that some of the genetic variants that nudge people towards schizophrenia for example, overlap with variants that nudge people towards ALS. 'It may not be use of the medication that increases ALS risk, but that the need for the medication is a signal that someone is already at increased genetic risk.' The authors of the study, from various Scandinavian institutions, note that depression, anxiety, and sleep disturbances have been shown to have 'detrimental effects' on brain cells, resulting in 'structural brain change concurrent with ALS'. MND, which includes ALS, is a progressive disease that affects around 5,000 adults in the UK, and was famously suffered by the physicist Stephen Hawking. In the study, which was conducted in Sweden, experts looked at 1,057 patients with an average age of 67, who were diagnosed with the disease between January 2015 and July 2023, as well as medications they had taken. Researchers followed the patients for an average of 1.33 years after their diagnosis. They matched these patients with a group of healthy controls to look for differences that could contribute to the disease. Writing in the journal JAMA open network, the researchers found prescribed use of anxiolytics was associated with 34 per cent increased risk of developing MND. Taking antidepressants, meanwhile, was linked with a 26 per cent raised chance, and sedatives and sleeping pills 21 per cent. The use of antidepressants pre-diagnosis in particular was also associated with a faster rate of functional decline. Lead author, Dr Charilaos Chourpiliadis, said that more work still needs to be done to understand the link. However, he said: 'Closer monitoring in younger patients with psychiatric symptoms might lead to an earlier ALS diagnosis.' Dr Brian Dickie, chief scientist at MND Association also flagged that the study may be flawed, because the most common genetic risk factor for ALS—a repeat expansion in the C9orf72 gene—is most prevalent in the Scandinavian population. 'A study in the Swedish population will most likely have a higher proportion of people with this particular genetic form of the disease,' he explained. 'Not only would higher use of psychiatric medication be likely, but this genetic form is also linked with faster progression and shorter survival, which could explain the association between psychiatric medication and more aggressive disease.'
